---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-070636"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:46:17.774053+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# FibroGen stockholders approve 2024 Equity Incentive Plan and elect directors

## Summary
- Class I directors elected: Thane Wettig (54.9M for), James Schoeneck (53.1M for), Maykin Ho (53.6M for).
- 2024 Equity Incentive Plan approved: 44.3M for, 10.8M against; plan adds 2.2M new shares plus prior plan reserve.
- Advisory vote on executive compensation approved: 53.5M for, 1.75M against.
- PricewaterhouseCoopers ratified as independent auditor for 2024: 72.5M for, 0.2M against.
- Say-on-pay frequency: every year preferred (54.8M votes).

## SEC filing metadata
- accession: 0000950170-24-070636
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024070636/0000950170-24-070636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024070636/fgen-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-070636
- JSON: https://secwatch.observer/filing/0000950170-24-070636.json
- Plain text: https://secwatch.observer/filing/0000950170-24-070636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.